2,869
edits
Nicotinamide Mononucleotide (NMN): Difference between revisions
Nicotinamide Mononucleotide (NMN) (view source)
Revision as of 11:54, 15 September 2023
, 15 September 2023→Studies
| Line 80: | Line 80: | ||
!Outcome | !Outcome | ||
|- | |- | ||
|Effect of oral administration of nicotinamide mononucleotide on clinical parameters and nicotinamide metabolite levels in healthy Japanese men <ref>https://www.jstage.jst.go.jp/article/endocrj/67/2/67_EJ19-0313/_article</ref> | |||
| | | | ||
* singe admission of up to 500 mg | |||
* oral admission at 9 AM | |||
| | | | ||
* 10 men | |||
* 40-60 years | |||
| | | | ||
* Admission was safe and well-tolerated in healthy men | |||
|- | |- | ||
| | | | ||